Navigation Links
Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival
Date:6/22/2009

SAN MARINO, Calif., June 22 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article (accessible online as of June 16, 2009 in Molecular Therapy, the Official Journal of The American Society of Gene Therapy, www.nature.com/mt/) documents the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body, while sparing normal cells and healthy tissues and organs. Following the FDA's designation of Rexin-G as an Orphan Drug for the treatment of soft tissue sarcoma and osteosarcoma in 2008, the results of these two independent studies represent a major step toward gaining Accelerated Approval of Rexin-G for osteosarcoma in the United States.

"It took several years of painstaking safety studies, followed by gradual, progressive dose escalations, to the point where tumor control was consistently demonstrated, said Dr. Erlinda M. Gordon, Medical Director of Epeius Biotechnologies. Yet the progressive development strategy has finally paid off with real dividends: (1) By establishing the overall safety of the tumor-targeted gene delivery platform first and foremost, (2) By establishing critical pharmacological thresholds of bioactivity and dose-dependent efficacy for a new class of biological anti-cancer agents in otherwise intractable cancers, and (3) By validating the potential of Rexin-G to control metastatic cancer with single-agent efficacy, whereas other targeted therapies must be used in combination with one or more toxic agents in order to achieve even marginal results. The dividends for the cancer patient can now be measured in terms of overall survival, which is considered to be the gold standard in terms of evaluating efficacy.

About Epeius Biotechnologies

Rexin-G is commercially available for the treatment of all solid tumors in the Republic of the Philippines, and has "fast track status" as a treatment for pancreatic cancer in the United States. Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its high-performance gene delivery systems. To learn more about ongoing clinical trials, licensing and corporate partnering opportunities, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotech
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sparta Systems Unveils TrackWise(R) Clinical Quality Management Solution
2. China Pharma Holdings, Inc. Announces SFDA Approval for Rosuvastatin Clinical Trials
3. Perceptive Informatics Launches the Next Level of Integration in its Industry-Leading eClinical Suite
4. Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations
5. CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting
6. Microsoft to Showcase Clinical Trial Solutions From Discovery to Approvals at Drug Information Associations 2009 Annual Meeting
7. Zysolin(TM) Pre-clinical Data Supports Once-a-day Dosing in Humans
8. Digital Mammography and Clinical Review Display Units Energising the European Markets for Medical Imaging Display Monitors, Finds Frost & Sullivan
9. Bariatric Advantage High Protein Meal Replacement Clinical Study Presented at European Congress on Obesity
10. International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials
11. Ambulatory Surgery Centers Pivotal in Moving Outpatient Surgical Services Into Less Expensive, Clinically Appropriate Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Nashville, Tennessee (PRWEB) , ... ... ... leader in strategic interoperability, today announced that the company will provide alerting ... platform. CIHIE has been recently awarded $1.7 million in federal funds as ...
(Date:12/5/2016)... Shrewsbury, PA (PRWEB) , ... December 05, 2016 , ... ... of necessity for the betterment of both the smaller rider and the horse. Smaller ... performance. The Saddle Sidekick is designed to fit over a properly fitted western saddle ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... of physical therapist assistants, under direct supervision of a licensed physical therapist, to ... therapy receives a consultation and treatment plan from a licensed physical therapist (PT) ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Facial Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at The Aesthetic ... Aesthetic & Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading ...
(Date:12/4/2016)... California (PRWEB) , ... December 03, 2016 , ... ... lower thirds, 4 transitions and many more tools allowing FCPX editors to create ... of Pixel Film Studios. , Perfect Harmony contains a beautifully designed 3D ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAKE OSWEGO, Ore. , Dec. 5, 2016 /PRNewswire/ ... in the BioInsight clinical study. The study evaluates the ... 2 insertion procedure in an office setting. ... ProMRI ® technology that is placed underneath a ... atrial fibrillation and syncope (fainting). Atrial fibrillation is a ...
(Date:12/5/2016)... Calif. , Dec. 5, 2016 Sanovas, ... technology accelerator, announced today the launch of its wholly owned ... Logo - http://photos.prnewswire.com/prnh/20161202/445250LOGO   Logo - http://photos.prnewswire.com/prnh/20161202/445251LOGO ... ... There ...
(Date:12/5/2016)... Dec. 5, 2016  Wellbridge Health and Gateway Health proudly ... solutions to Medicare and Medicaid plan members with specific high ... the unique needs of this group of consumers, Wellbridge combines ... philosophies to provide insight into members, daily behaviors and lifestyle. ... , , ...
Breaking Medicine Technology: